Chronic Kidney Disease and Vaccination

Jessica Emli^*
*Correspondence: Jessica Emli, Institute for Biomedical Ethics and History of Medicine, University of Zurich, Zurich, Switzerland, Email:

Short Communication

Infections are the second leading cause of death among those with chronic renal disease, after cardiovascular disease. In people with renal diseases, vaccination is a vital part of keeping their health and well-being. From childhood through adulthood, the epidemiologic landscape for multiple vaccine-preventable illnesses is shifting, as is the public's misplaced fear of harm. Inadequate vaccine protection in this high-risk population of chronic renal disease patients has been linked to a number of causes. As a result, new vaccine techniques for kidney illness have recently been developed. The latest research and immunisation recommendations for people with kidney illness who require renal replacement therapy are reviewed in this article (dialysis and transplant) [1-3].

The substantial morbidity and mortality of patients with end-stage renal disease (ESRD) prompted the creation of a number of guidelines designed to improve the care of dialysis patients and, more recently, those with early stages of chronic kidney disease (CKD). Although cardiovascular disease has received a lot of attention, infectious disease is the second leading cause of death in people with late-stage CKD. More than 660,000 Americans are being treated for kidney failure, according to the US Renal Data System Annual Data Report, with 468,000 on dialysis and more than 193,000 getting a functioning kidney transplant. Infections with bacteremia and/or septicemia in patients with CKD who are on dialysis and patients with kidney and other organ transplants, in addition to cardiovascular events and bacterial pneumonias, account for a share of hospitalizations [4,5].

In patients with CKD and ESRD, vaccine-preventable illnesses account for just a small portion of the infectious burden. Vaccination procedures have resulted in lower infection rates and, as a result, lower morbidity and death. It's reasonable to assume that widespread vaccination would lower the overall cost of kidney disease patient care while also improving patient well-being. Despite this, CKD patients get immunised at a lower rate than the general population. Because of reduced immunity, immunosuppressive medications, and dialysis, patients with CKD, regardless of the aetiology, are known to be vulnerable to vaccine-preventable diseases. Reduced vaccination efficacy and safety concerns for transplant candidates or recipients have impeded efforts to increase vaccine delivery rates in these patients.

Immune function

Several advancements in understanding immunologic response have led to novel designs for vaccination approaches during the last decade. Infectionrelated consequences are more common in children with undeveloped immune systems and the elderly with comorbidities, and CKD may be a risk multiplier. The reduction in vaccination effectiveness across the phases of CKD has been affected by a variety of innate and adaptive immunity defects rather than a single anomaly in immune function. Inherited immunity may be to blame for a poor vaccination response in patients with severe kidney disease. Furthermore, incorrect antigen presentation to antigen-presenting cells for their destruction is caused by adaptive immune malfunction with reduced B and T cells and diminished monocyte function. As a result, memory cells are harmed, and vaccination antibodies are produced insufficiently [6,7-9].

Haemodialysis (HD) and peritoneal dialysis (PD) patients both suffer a disturbance in the protective epidermis barriers against infections, putting them at risk for bacteraemia, exit-site infections, and peritonitis. Immunoglobulin depletion during peritoneal dialysis has been linked to a higher risk of infection. Immunosuppressive medications suppress main defensive mechanisms in patients with idiopathic and autoimmune glomerulopathies, as well as transplant recipients. Transplant candidates should be inoculated early in the course of their disease because the response to many vaccines is reduced in organ failure [10].

Vaccination is still a vital part of care for individuals with CKD, although it's often disregarded. Vaccine-induced serconversion is rare in severe CKD, with less than 90% of vaccinations causing serconversion. In patients with advanced CKD, many techniques have been used to boost the vaccine-induced seroconversion rate. In this population, traditional immunisation techniques are ineffective in terms of eliciting positive host responses. From childhood to adulthood, the epidemiologic landscape for multiple vaccine-preventable illnesses is shifting, raising safety concerns. To increase the immunisation rate and efficacy, researchers are experimenting with different injection modes, adjuvants, and immunostimulants to improve the immunogenicity of existing recombinant vaccines, and the introduction of mammalian-cell derived vaccines (third-generation vaccines). To compare the efficiency of combining vaccination antigens to increase protective responses and immunologic memory, more study is needed. Nonetheless, as we wait for new vaccinations, present immunisation regimens in the CKD population must be aggressively promoted.

References

1. Naqvi, Sakina B., and Allan J. Collins. "Infectious complications in chronic kidney disease." Adv Chronic Kidney Dis 13 (2006): 199-204.

Google Scholar, Crossref, Indexed at

2. Kosmadakis, Georges, Julie Albaret, Enrique Da Costa Correia and Didier Aguilera. "Vaccination practices in dialysis patients: A narrative review." Semin Dial 31 (2018):  507-518.

Google Scholar, Crossref, Indexed at

3. Ventola, C. Lee. "Immunization in the United States: recommendations, barriers, and measures to improve compliance: part 1: childhood vaccinations." Pharm Ther 41 (2016): 426.

Google Scholar, Indexed at

4. Annunziata, Kathy, Aaron Rak, Heather Del Buono and Girishanthy Krishnarajah. "Vaccination rates among the general adult population and high-risk groups in the United States." PLoS One 7 (2012): e50553.

Google Scholar, Crossref, Indexed at

5. Bitsori, Maria and Emmanouil Galanakis. "Vaccine-preventable infection morbidity of patients with chronic kidney disease and cocoon vaccination strategies." Expert Rev Vaccines 14 (2015): 1385-1395.

Google Scholar, Crossref, Indexed at

6. Kato, Sawako, Michal Chmielewski, Hirokazu Honda and Bengt Lindholm. "Aspects of immune dysfunction in end-stage renal disease." Clin J Am Soc Nephrol 3 (2008): 1526-1533.

Google Scholar, Crossref, Indexed at

7. Ishigami, Junichi and Kunihiro Matsushita. "Clinical epidemiology of infectious disease among patients with chronic kidney disease." Clin Exp Nephrol 23 (2019): 437-447.

Google Scholar, Crossref, Indexed at

8. Litjens, Nicolle HR, Corné J. van Druningen and Michiel GH Betjes. "Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes." Clin Immunol 118 (2006): 83-91.

Google Scholar, Crossref, Indexed at

9. Meier, Pascal, Eric Dayer, Edouard Blanc and Jean-Pierre Wauters. "Early T cell activation correlates with expression of apoptosis markers in patients with end-stage renal disease." J Am Soc Nephrol 13 (2002): 204-212.

Google Scholar, Crossref, Indexed at

10. Anding, Kirsten, Peter Gross, Jan M. Rost, and Enno Jacobs. "The influence of uraemia and haemodialysis on neutrophil phagocytosis and antimicrobial killing." Nephrol Dial Transplant 18 (2003): 2067-2073.

Google Scholar, Crossref, Indexed at